ZyVersa Therapeutics Inc. Watch

from 8-K 1 page Underwriting agreement

from S-1/A 8 pages This Letter (The “Agreement”) Constitutes the Agreement Between A.G.P./ALLIANCE Global Partners, as Sole Placement Agent (The “Placement Agent”), and ZyVersa Therapeutics, Inc., a Company Incorporated Under the Laws of the State of Delaware (The “Company”), That the Placement Agent Shall Serve as the Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of Units of Registered Securities of the Company With Each Unit Consisting of a Combination of (I) One Share (A “Share” And, Collectively, the “Shares”) of the Company’s Common Stock, Par Value $0.0001 Per Share (The “Common Stock”), (II) One Warrant to Purchase a Share of Common Stock of the Company (The “Common Warrants”), and/or (III) Pre-Funded Warrants to Purchase One Share of Common Stock (The “Pre-Funded Warrants”, and Together With the Common Warrants, the “Warrants,” and Collectively With the Shares, the “Securities”), Depending on the Beneficial Ownership Percentage of the Purchaser of the Common Stock Following Its Purchase

from S-1/A 8 pages This Letter (The “Agreement”) Constitutes the Agreement Between A.G.P./ALLIANCE Global Partners, as Lead Placement Agent (The “Placement Agent”), and ZyVersa Therapeutics, Inc., a Company Incorporated Under the Laws of the State of Delaware (The “Company”), That the Placement Agent Shall Serve as the Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of Units of Registered Securities of the Company With Each Unit Consisting of a Combination of (I) One Share (A “Share” And, Collectively, the “Shares”) of the Company’s Common Stock, Par Value $0.0001 Per Share (The “Common Stock”), (II) One Warrant to Purchase a Share of Common Stock of the Company (The “Common Warrants”), and/or (III) Pre-Funded Warrants to Purchase One Share of Common Stock (The “Pre-Funded Warrants”, and Together With the Common Warrants, the “Warrants,” and Collectively With the Shares, the “Securities”), Depending on the Beneficial Ownership Percentage of the Purchaser of the Common Stock Following Its Purchase

from S-1/A 8 pages This Letter (The “Agreement”) Constitutes the Agreement Between A.G.P./ALLIANCE Global Partners, as Lead Placement Agent (The “Placement Agent”), and ZyVersa Therapeutics, Inc., a Company Incorporated Under the Laws of the State of Delaware (The “Company”), That the Placement Agent Shall Serve as the Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of Units of Registered Securities of the Company With Each Unit Consisting of a Combination of (I) One Share (A “Share” And, Collectively, the “Shares”) of the Company’s Common Stock, Par Value $0.0001 Per Share (The “Common Stock”), (II) One Warrant to Purchase a Share of Common Stock of the Company (The “Common Warrants”), and/or (III) Pre-Funded Warrants to Purchase One Share of Common Stock (The “Pre-Funded Warrants”, and Together With the Common Warrants, the “Warrants,” and Collectively With the Shares, the “Securities”), Depending on the Beneficial Ownership Percentage of the Purchaser of the Common Stock Following Its Purchase

from S-1/A 6 pages This Letter (The “Agreement”) Constitutes the Agreement Between A.G.P./ALLIANCE Global Partners, as Lead Placement Agent (The “Placement Agent”), and ZyVersa Therapeutics, Inc., a Company Incorporated Under the Laws of the State of Delaware (The “Company”), That the Placement Agent Shall Serve as the Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of Units of Registered Securities of the Company With Each Unit Consisting of a Combination of (I) One Share (A “Share” And, Collectively, the “Shares”) of the Company’s Common Stock, Par Value $0.0001 Per Share (The “Common Stock”), (II) One Warrant to Purchase a Share of Common Stock of the Company (The “Common Warrants”), and/or (III) Pre-Funded Warrants to Purchase One Share of Common Stock (The “Pre-Funded Warrants”, and Together With the Common Warrants, the “Warrants,” and Collectively With the Shares, the “Securities”), Depending on the Beneficial Ownership Percentage of the Purchaser of the Common Stock Following Its Purchase

from SC 13G 2 pages Joint Filing Agreement

from 8-K 6 pages A.G.P./ALLIANCE Global Partners 590 Madison Avenue, 28th Floor New York, Ny 10022 December 20, 2021

from 8-K 32 pages 7,500,000 Units Larkspur Health Acquisition Corp. Underwriting Agreement

from S-1/A 31 pages 7,500,000 Units Larkspur Health Acquisition Corp. Underwriting Agreement

from S-1/A 6 pages A.G.P./ALLIANCE Global Partners 590 Madison Avenue, 28th Floor New York, Ny 10022 , 2021

from S-1/A 31 pages 7,500,000 Units Larkspur Health Acquisition Corp. Underwriting Agreement